Human PD-L1 / B7-H1 / CD274 Protein (Fc Tag)
B7-H,B7-H1,B7H1,PD-L1,PDCD1L1,PDCD1LG1,PDL1
- 100ug (NPP1568) Please inquiry
Catalog Number | P10084-H02H |
---|---|
Organism Species | Human |
Host | Human Cells |
Synonyms | B7-H,B7-H1,B7H1,PD-L1,PDCD1L1,PDCD1LG1,PDL1 |
Molecular Weight | The recombinant mature human B7-H1/Fc is a disulfide-linked homodimeric protein. The reduced monomer consists of 459 amino acids and predicts a molecular mass of 52 kDa. As a result of glycosylation, the rh B7-H1/Fc monomer migrates as an approximately 65-70 kDa protein in SDS-PAGE under reducing conditions. |
predicted N | Phe 19 |
SDS-PAGE | |
Purity | > 95 % as determined by SDS-PAGE |
Protein Construction | A DNA sequence encoding the N-terminal segment (Met 1-Thr 239) of the extracellular domain of human B7-H1 (NP_054862.1) was expressed with C-terminal fused Fc region of human IgG1. |
Bio-activity | Measured by its binding ability in a functional ELISA . Immobilized human PD-1 at 10 μg/ml (100 μl/well) can bind recombinant human B7-H1 / PD-L1 / Fc chimera with a linear range of 0.02-0.4 μg/ml . |
Research Area | Immunology |Innate Immunity |Monocytes/Macrophages |Macrophage Markers |
Formulation | Lyophilized from sterile PBS, pH 7.4 1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. |
Background | Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers. |
Reference |